名臣健康(002919) - 2018 Q3 - 季度财报

Financial Performance - Operating revenue for the current period was ¥114,890,419.33, down 27.04% year-on-year[8] - Net profit attributable to shareholders decreased by 55.08% to ¥6,024,605.81 compared to the same period last year[8] - Net profit attributable to shareholders after deducting non-recurring gains and losses fell by 71.24% to ¥3,593,594.50[8] - Basic earnings per share decreased by 68.18% to ¥0.07[8] - The weighted average return on net assets was 1.11%, down 3.34% from the previous year[8] - The estimated net profit for 2018 is expected to decrease by 10.00% to 30.00%, ranging from ¥3,395.62 to ¥4,365.8 million[18] Assets and Liabilities - Total assets decreased by 4.24% to ¥655,677,427.63 compared to the end of the previous year[8] - Cash and cash equivalents decreased by 62.38% to ¥159,599,511.51 due to the purchase of financial products[16] - Accounts receivable increased by 69.26% to ¥41,911,389.02, primarily due to credit sales not yet due for collection[16] - Long-term prepaid expenses decreased by 55.84% to ¥1,113,786.67, attributed to normal amortization of advertising endorsement fees[16] - Deferred income decreased by 85.71% to ¥100,000.00, mainly due to the recognition of income from technology projects[16] Cash Flow - The net cash flow from operating activities increased by 221.88% to ¥17,126,744.75 compared to the same period last year[8] - Operating cash flow net amount improved by 42.75% to -¥43,067,577.85, reflecting a relative decrease in cash outflows from operating activities[16] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 14,557[12] - The largest shareholder, Chen Qinfang, holds 49.34% of the shares, amounting to 40,172,000 shares, with 6,500,000 shares pledged[12] Non-Recurring Items - Non-recurring gains and losses totaled ¥8,215,311.43 for the year-to-date[9] - The company reported a significant increase in non-operating income by 1386.63% to ¥3,449,000.04, mainly due to new listing rewards[16] Investments and Financial Management - Investment income increased by 115.14% to ¥5,650,109.71, driven by higher returns from financial products[16] - Total entrusted financial management amounts to ¥27,000,000, with an unexpired balance of ¥20,000,000[23] - The company has no overdue commitments or non-operating fund occupation by controlling shareholders during the reporting period[21]